The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
SR 4233 (Tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours
Open accessAbstract
SR 4233 (3-amino-1,2,4-benzotriazine 1,4-dioxide, WIN 59075, tirapazamine) is the lead compound in a new class of bioreductive anticancer drugs, the benzotriazine di-N-oxides. It is currently undergoing Phase I clinical testing. The preferential tumour cell killing of SR 4233 is a result of its high specific toxicity to cells at low oxygen tensions. Such hypoxic cells are a common feature of solid tumours, but not normal tissues, and are resistant to cancer therapies including radiation and some anticancer drugs. The killing of these tumour cells by SR 4233, particularly when given on multiple occasions, can increase total tumour cell killing by fractionated irradiation by several orders of magnitude without increasing toxicity to surrounding normal tissues. Topics covered in this review include the rationale for developing a hypoxic cytotoxic agent, the cytotoxicity of SR 4233 as a function of oxygen concentration, the mechanism of action of the drug and its intracellular target and the in vivo evidence that the drug may be useful as an adjunct both to radiotherapy and chemotherapy. Finally, the major unanswered questions on the drug are outlined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vaupel, P. W., Schlenger, K., Knoop, C., & Höckel, M. (1991) · PubMed · Cited by 952
Gatenby, R. A., Kessler, H. B., Rosenblum, J. S., Coia, L. R., Moldofsky, P. J., Hartz, W. H., & Broder, G. J. (1988) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(88)90002-8 · Cited by 798
Bioactivation as a Model for Drug Design Bioreductive Alkylation
Moore, H. W. (1977) · Science · doi:10.1126/science.877572 · Cited by 430
Definitive evidence for hypoxic cells influencing cure in cancer therapy.
Bush, R. S., Jenkin, R. D. T., Allt, W. E. C., Beale, F. A., Bean, H. A., Dembo, A. J., & Pringle, J. F. (1978) · PubMed Central · Cited by 416
Tumor hypoxia: its impact on cancer therapy
Moulder, J. E., & Rockwell, S. (1987) · Cancer and Metastasis Reviews · doi:10.1007/bf00055376 · Cited by 414
SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells
Zeman, E. M., Brown, J. M., Lemmon, M. J., Hirst, V. K., & Lee, W. W. (1986) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(86)90267-1 · Cited by 402
Self-citationOxygenation of carcinomas of the uterine cervix: evaluation by computerized O2 tension measurements.
Höckel, M., Schlenger, K., Knoop, C., & Vaupel, P. W. (1991) · PubMed · Cited by 350
Cornforth, M. N., & Bedford, J. S. (1987) · Radiation Research · doi:10.2307/3576926 · Cited by 332
RADIOTHERAPY AND HYPERBARIC OXYGEN IN HEAD AND NECK CANCER
Henk, J. M., & Smith, C. W. (1977) · The Lancet · doi:10.1016/s0140-6736(77)90117-9 · Cited by 320
Therapeutic attack of hypoxic cells of solid tumors: presidential address.
Sartorelli, A. C. (1988) · PubMed · Cited by 255
Cited by
Targeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
Exploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828
Self-citationDrug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
Overcoming the Achilles' heel of photodynamic therapy
Fan, W., Huang, P., & Chen, X. (2016) · Chemical Society Reviews · doi:10.1039/c6cs00616g · Cited by 1,684
Hypoxia signalling through mTOR and the unfolded protein response in cancer
Wouters, B. G., & Koritzinsky, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2501 · Cited by 894
Metadata
- Authors
- Brown, J.
- Venue
- British Journal of Cancer
- Published
- 1993-06
- Volume
- 67
- Issue
- 6
- Pages
- 1163-1170
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2145953677
- Cited by
- 366
- References
- 44
- FWCI
- 7.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SR 4233 (Tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. https://app.cochat.ai/papers/10.1038/bjc.1993.220
- The paper
- Brown, J. (1993). SR 4233 (Tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. British Journal of Cancer. https://doi.org/10.1038/bjc.1993.220
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.